Institution Directory

Clinical trials at Vanderbilt University Medical Center

Sites in Nashville, TN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1271

Shown on this page

Current sort

Live official records

Conditions: Allergic Diseases, Food Allergy, Atopic Dermatitis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 0 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2032
U.S. locations: 13
States / cities: Little Rock, Arkansas • Stanford, California • Denver, Colorado + 10 more

Conditions: DIEP Flap Breast Reconstruction
Interventions: Single-Port Robotic System; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Gastroschisis
Interventions: 35-week delivery, 38-week delivery; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 38
States / cities: Phoenix, Arizona • Loma Linda, California • Stanford, California + 30 more

Conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Interventions: NS-229, Placebo; Drug
Lead sponsor: NS Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Denver, Colorado • Rochester, Minnesota • Cleveland, Ohio + 4 more

Conditions: Kidney Diseases, Kidney Failure, Kidney Disease, Chronic
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • San Francisco, California • Miami, Florida + 12 more

Conditions: HIV, Alcohol, Smoking Cigarette, Cardiovascular Disease Prevention
Interventions: Semaglutide (Rybelsus®), Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), AML Arising From Antecedent Hematologic Disorder (AHD), AML Arising After Exposure to Genotoxic Injury
Interventions: AG-120, AG-221, cytarabine, daunorubicin, idarubicin, mitoxantrone, etoposide; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 42
States / cities: Sun City, Arizona • Glendale, California • Inglewood, California + 38 more

Conditions: Duchenne Muscular Dystrophy
Interventions: wearable technology; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 10 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Systemic Lupus Erthematosus (SLE)
Interventions: 2-HOBA acetate (2-Hydroxybenzlamine acetate), Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Obesity, Insulin Resistance, Hypertension, Metabolic Cardiovascular Syndrome
Interventions: Angiotensin-(1-7), Saline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Autism, Autism Spectrum Disorder
Interventions: Reciprocal Imitation Training, music-enhanced Reciprocal Imitation Training; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Months to 36 Months
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

About this Vanderbilt University Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Vanderbilt University Medical Center in Nashville, TN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Vanderbilt University Medical Center

Filter and sort this campus

Live official records

Systems Biology of Early Atopy

Feasibility and Safety of Single-Port Robotic-Assisted Deep Inferior Epigastric Pedicle Flap Harvest

Gastroschisis Outcomes of Delivery (GOOD) Study

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

Wearable Technology to Evaluate Hyperglycemia and HRV in DMD

2-HOBA in Systemic Lupus Erythematosus

Metabolic Effects of Angiotensin-(1-7)

Reciprocal Imitation Training and Musical Rhythm Sensitivity in Autistic Toddlers

About this Vanderbilt University Medical Center institution page